Trial reportThyroid : official journal of the American Thyroid Association2022
Dabrafenib Versus Dabrafenib + Trametinib in
Registry-linked trialOpen access · greenAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
In one paragraph
Trial report in Thyroid : official journal of the American Thyroid Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01723202 (A Randomized Phase 2 Study of Single Agent Dabrafenib), which is not on this map. Cited by 94 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 7 pooled it
13.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
Who cites it
94 citing papers in PubMed, 7 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- BRAF/MEK inhibitors for redifferentiation in patients with radioiodine refractory thyroid cancer: A systematic review and Meta-Analysis.Endocrine · 2026Pooled it
- Chemotherapy-related hand-foot syndrome and hand-foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study team.International journal of clinical oncology · 2025Pooled it
- Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).European journal of nuclear medicine and molecular imaging · 2025Guideline
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.Endocrine journal · 2025Guideline
- Association of radiomic features with genomic signatures in thyroid cancer: a systematic review.Journal of translational medicine · 2024Pooled it
- SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.International journal of clinical oncology · 2026Trial
- Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.European thyroid journal · 2026Trial
- Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).Frontiers in endocrinology · 2024Trial
- A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.Nature medicine · 2023Trial
- Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patients.Endocrine journal · 2026Article
- Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy.Cancer innovation · 2026Review
- Thyroid Cancer: Epidemiology, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2026Review
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.Cell reports. Medicine · 2026Article
- Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.NPJ precision oncology · 2026Article
- Loss of CSE couples with BRAF V600E to fuel thyroid cancer metastatic progression through zinc-dependent activation of the EMT machinery.Journal of experimental & clinical cancer research : CR · 2026Article
- Clinical outcomes in older adults with advanced thyroid cancer.The oncologist · 2026Article
- Continuous administration of lenvatinib after first documented disease progression in patients with radioiodine-refractory thyroid cancer.Endocrine · 2026Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Naifa L BusaidyDivision of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bhavana KondaDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Lai WeiDepartment of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Lori J WirthDivision of Hematology and Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-2629-2289
Catherine DevineDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gregory A DanielsDivision of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla, California, USA.
Jonas A DeSouzaDivision of Medical Oncology, The University of Chicago, Chicago, Illinois, USA.
Ming PoiDepartment of Pharmacology, The Ohio State University, Columbus, Ohio, USA.
Nathan D SeligsonDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Maria E CabanillasDivision of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jennifer A SiposDivision of Endocrinology, Diabetes, and Metabolism, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Matthew D RingelDivision of Endocrinology, Diabetes, and Metabolism, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Ann-Kathrin EisfeldDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Cynthia TimmersTranslational Sciences Discovery Lab, Incyte Corporation, Wilmington, Delaware, USA.
Manisha H ShahDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
The Ohio State University · USThe University of Texas MD Anderson Cancer Center · USIncyte (United States) · USMassachusetts General Hospital · USUniversity of California San Diego · USUniversity of Chicago Medical Center · USUniversity of Florida · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3MRole of p21-activated kinases in thyroid cancerR01CA227847 · NCI · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$1.9MNCI NIH HHS P30 CA016058NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA227847
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaMelanomaThyroid NeoplasmsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsHumansImidazolesIodine RadioisotopesMutationOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesBRAF protein, humandabrafenibImidazolesIodine RadioisotopesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesBRAFkinase inhibitortargeted therapythyroid cancer
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT01723202ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.